vTv Therapeutics reports additional positive PhII data; Shanghai Henlius prices $410 million IPO at bottom of range
→ vTv Therapeutics — focused on the development of oral small molecule drug candidates — has unveiled additional positive data from its Phase II Simplici-T1 study in patients with type 1 diabetes (T1D). CSO Carmen Valcarce presented new continuous glucose monitor (CGM) and insulin dose data from patients with complete CGM profiles in the completed Phase II – Part 1 of the study, which includes:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.